Overview

First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years

Status:
Active, not recruiting

Trial end date:
2022-11-30

Target enrollment:

Participant gender:

Summary

The objective of this study is to test the efficacy and toxicity of a combined OBINUTUZUMAB/bendamustine therapy or single agent OBINUTUZUMAB in younger (< 60 years) medically non-fit, 'compromised' patients and in all older patients (≥ 60 years). For the assessment of the antilymphoma activity the overall response rate (ORR)" will be applied as primary endpoint. Overall response is defined as complete or partial response after 19 - 21 weeks.

Phase:

Phase 2

Details

Lead Sponsor:

Prof. Dr. Wolfgang Hiddemann

Collaborators:

Hoffmann-La Roche
Mundipharma Research GmbH & Co KG

Treatments:

Bendamustine Hydrochloride
Obinutuzumab